OMARINI, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.170
EU - Europa 4.862
AS - Asia 3.835
SA - Sud America 599
AF - Africa 104
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 12
Totale 17.612
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.049
IT - Italia 1.299
CN - Cina 1.180
SG - Singapore 1.131
GB - Regno Unito 911
IE - Irlanda 830
HK - Hong Kong 554
BR - Brasile 480
DE - Germania 469
SE - Svezia 365
VN - Vietnam 253
RU - Federazione Russa 203
FR - Francia 168
ID - Indonesia 134
FI - Finlandia 123
IN - India 106
UA - Ucraina 103
TR - Turchia 83
KR - Corea 76
CA - Canada 66
BG - Bulgaria 60
JP - Giappone 53
AR - Argentina 47
NL - Olanda 45
PL - Polonia 44
LT - Lituania 42
IQ - Iraq 41
TW - Taiwan 39
MX - Messico 33
ES - Italia 30
BD - Bangladesh 29
BE - Belgio 29
CZ - Repubblica Ceca 28
AU - Australia 27
EG - Egitto 27
ZA - Sudafrica 25
MY - Malesia 24
IR - Iran 23
AT - Austria 22
PK - Pakistan 20
CO - Colombia 18
CL - Cile 17
EC - Ecuador 17
RO - Romania 15
MD - Moldavia 12
VE - Venezuela 12
CH - Svizzera 11
EU - Europa 10
KE - Kenya 9
PH - Filippine 9
MA - Marocco 8
IL - Israele 7
SA - Arabia Saudita 7
TN - Tunisia 7
DO - Repubblica Dominicana 6
GR - Grecia 6
HU - Ungheria 6
NP - Nepal 6
TH - Thailandia 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
GH - Ghana 5
MT - Malta 5
RS - Serbia 5
AL - Albania 4
CR - Costa Rica 4
HN - Honduras 4
LB - Libano 4
NG - Nigeria 4
NO - Norvegia 4
PE - Perù 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
ET - Etiopia 3
IS - Islanda 3
JO - Giordania 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LV - Lettonia 3
MK - Macedonia 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
BW - Botswana 2
CY - Cipro 2
DK - Danimarca 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
PY - Paraguay 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
Totale 17.587
Salva come PNG Salva come JPEG
Città #
Santa Clara 959
Ashburn 855
Dublin 826
Singapore 736
Fairfield 636
Chandler 592
Hong Kong 536
Dallas 470
Southend 420
Hefei 337
Houston 298
Woodbridge 294
Nyköping 259
Seattle 254
Wilmington 240
Ann Arbor 227
Dearborn 215
Beijing 213
London 206
Cambridge 176
New York 169
Los Angeles 157
Jacksonville 144
Modena 141
Chicago 122
Jakarta 108
Munich 107
Shanghai 91
Milan 87
Helsinki 86
Ho Chi Minh City 84
The Dalles 77
San Diego 74
Moscow 71
Bologna 69
Seoul 68
Fremont 62
Rome 61
Princeton 60
Sofia 60
Redwood City 52
Council Bluffs 46
Hanoi 46
Eugene 44
São Paulo 43
Dong Ket 41
Frankfurt am Main 40
Izmir 37
Salt Lake City 37
Tokyo 37
Warsaw 34
Bremen 33
Buffalo 32
Enfield 32
Guangzhou 32
Lauterbourg 30
Reggio Emilia 30
Columbus 29
Phoenix 29
Baghdad 28
Parma 27
San Giuliano Milanese 26
Elk Grove Village 25
Falls Church 25
Orem 25
Brooklyn 24
Portsmouth 24
Redondo Beach 24
Paris 23
Tampa 23
Lawrence 22
Asyut 21
Brussels 21
Nuremberg 21
Denver 19
Kent 18
Poplar 17
Toronto 17
Turku 17
Atlanta 15
Brno 15
Düsseldorf 15
Banqiao 14
Boardman 14
Absecon 13
Belo Horizonte 13
Genoa 13
Johannesburg 13
Mexico City 13
Mumbai 13
Porto Alegre 13
Amsterdam 12
Boston 12
Chisinau 12
Des Moines 12
Montreal 12
Nanjing 12
Norwalk 12
Ottawa 12
Palermo 12
Totale 12.070
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 520
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 383
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 360
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 354
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 352
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 323
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 320
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 319
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 318
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 316
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 312
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 302
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 298
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 291
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 282
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 281
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 280
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 278
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 269
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 269
Immune characterization of breast cancer metastases: prognostic implications. 267
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 262
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 262
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 261
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 254
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 250
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 250
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 249
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 249
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 248
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 240
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 238
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 228
PROFILO MUTAZIONALE DI TUMORI MAMMARI HER2 POSITIVI TRATTATI CON CHEMIOTERAPIA NEOADIUVANTE​ 226
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 223
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 222
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 220
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 220
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 219
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 212
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 212
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 211
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 211
Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. 207
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 205
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges 204
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 203
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 201
The role of exosomes in breast cancer diagnosis 191
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 188
Lapatinib and renal impairment: a case report 183
TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis 181
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 181
Breast cancer follow-up: a national survey of current clinical practice by the centers of Italian Oncological Group of Clinical Research (GOIRC). 180
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 179
Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study. 178
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it! 171
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 170
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 170
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 170
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 169
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact 168
Prognostic role of HER2 loss after neoadjuvant therapy in patients with HER2-positive operable breast cancer 168
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 155
Next Generation Sequencing (NGS): a possible game changer in metastatic breast cancer 152
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affectclinical outcome of metastatic breast cancer patients 149
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 142
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 132
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 129
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib 127
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 124
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist 124
TDM-1 efficacy in trastuzumabpertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis 120
Atezolizumab-Related Sarcoidosis-Like Reaction in Early Breast Cancer Patient: Know It To Diagnose It: A Case Report with Review of the Literature 117
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 116
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 110
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer (HR+/HER2- mBC): regulatory aspects and clinical impact in Europe 108
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 105
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 87
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 85
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments 82
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer 62
Totale 17.754
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021959 0 0 0 0 0 129 70 180 102 195 124 159
2021/20221.368 77 147 117 58 51 110 63 71 131 126 251 166
2022/20232.647 191 266 146 186 174 202 47 156 960 50 168 101
2023/20241.429 75 65 102 138 175 130 160 211 54 64 102 153
2024/20254.164 141 53 127 268 814 592 319 257 410 286 335 562
2025/20263.985 567 251 924 798 1.108 337 0 0 0 0 0 0
Totale 17.754